Drugs / PRE-PEN
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PRE-PEN | — | 1974-07-25 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06406114 | May 2025 → Jul 2028 expected | anaphylaxis, drug allergy, drug pseudoallergy | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01818336 | Dec 2012 → Jun 2013 | IgE responsiveness, atopic | AllerQuest LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRE-PEN | “PRE-PEN (benzylpenicilloyl polylysine)” NCT01818336 ↗ |
| Known as | PRE-PEN (benzylpenicilloyl polylysine) | “PRE-PEN (benzylpenicilloyl polylysine)” NCT01818336 ↗ |